Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1432-1438

  Turan, T ^a   Karacay, O ^a   Tulunay, G ^a   Boran, N ^a   Koc, S ^a   Bozok, S ^a   Kose, M F ^a  

^a Etlik Maternity and Women's Health Teaching Hospital   (Turkey)

Author keywords

EMA CO; Gestational trophoblastic neoplasia; Toxicity

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD GROUP; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHORIOCARCINOMA; CLINICAL ARTICLE; CONSTIPATION; DEATH; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LIVER METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PAIN; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TOXICITY; TREATMENT FAILURE; TROPHOBLASTIC TUMOR; WORLD HEALTH ORGANIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; LEUKOPENIA; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33745090480     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00606.x     Document Type: Article

References (21)

1. Wong LC Choo YC Ma HK. Primary oral etoposide therapy in gestational trophoblastic disease. Cancer 1986 58 : 14 7.
2. Berkowitz RS Goldstein DP Bernstein MR. Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986 23 : 111 8.
3. Jones WB. Gestational trophoblastic disease: What have we learned in past decade? Am J Obstet Gynecol 1990 162 : 1286 95.
4. Soto-Wright V Goldstein DP Bernstein MR Berkowitz RS. The management of gestational trophoblastic tumors with etoposide, methotrexate and actinomycin D. Gynecol Oncol 1997 64 : 156 9.
5. Lurain JR Sciarra JJ. Study and treatment of gestational trophoblastic disease at the John I. Trophoblastic Disease Center, 1962-1990. Eur J Gynaecol Oncol 1991 12 : 425 8.
6. Jones WB Cardinale C Lewis JL Jr.. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int J Gynecol Cancer 1997 7 : 27 33.
7. Berkowitz RS Goldstein DP Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol 1984 19 : 173 81.
8. Surwit EA Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol 1980 55 : 565 70.
9. Bagshawe KD. Risk and prognosis factors in trophoblastic neoplasia. Cancer 1976 38 : 1373 85.
10. World Health Organization (WHO). Scientific group: gestational trophoblastic disease. Technical report series no. 692, Geneva, Switzerland : WHO, 1983 : 1 81.
11. FIGO Oncology Committee Report. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet 2002 77 : 285 7.
12. Newlands ES Bagshawe KD Begent RHJ Rustin GJS Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high-risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991 98 : 550 7.
13. WHO handbook for reporting results of cancer treatment. WHO Offset Publication, No. 148. Geneva, Switzerland : WHO, 1979.
14. Schink JC Singh DK Rademaker AW Miller DS Lurain JR. Etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992 80 : 817 20.
15. Kim SJ Bae SN Kim JH Kim CJ Jung JK. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol Oncol 1998 71 : 247 53.
16. Bower M Newlands ES Holden L et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997 15 : 2636 43.
17. Soper JT Evans AC Clarke-Pearson DL Berchuck A Rodriguez G Hammond CB. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/ cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 1994 83 : 113 7.
18. Escobar PF Lurain JR Singh DK Bozorgi K Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine chemotherapy. Gynecol Oncol 2003 91 : 552 7.
19. Bolis G Bonazzi C Landoni F et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988 31 : 139 444.
20. BuBeshter B Berkowitz RS Goldstein DP Cramer DW Bernstein MR. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965-1985. Obstet Gynecol 1987 69 : 390 5.
21. Rustin GJS Newlands ES Lutz J-M et al. Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996 14 : 2769 73.